Illumina Expects to Exceed Financial Guidance for the First Quarter of 2006
Thursday April 6, 6:53 pm ET
Management to Host Conference Call on April 18 Following Release of First Quarter 2006 Results
SAN DIEGO--(BUSINESS WIRE)--April 6, 2006--Illumina, Inc. (NASDAQ:ILMN - News) announced today that it expects to exceed both the revenue and net income per share guidance for the first quarter of 2006, originally provided on February 1, 2006. In February, the Company disclosed that it expected total revenue for the first quarter to range between $22 million and $24 million and net income per basic and diluted share, excluding the impact of stock compensation expense, between breakeven and $0.02.
ADVERTISEMENT
Illumina will issue its results for the first quarter of fiscal year 2006 and update its financial guidance for the remainder of the year following the close of the market on Tuesday, April 18, 2006.
Company management will host a conference call with analysts, investors and other interested parties on the same day at 2:00 p.m. Pacific Time to discuss financial and operating results and related business matters. Individuals may listen to the call by dialing 800 289-0507 (international callers should dial +1 913 981-5540) or by accessing the live webcast under the "Investors" tab of Illumina's website at: www.illumina.com.
The webcast of the conference call will be archived for one year and will be available on the Investors page of the Company's website at www.illumina.com.
About Illumina
Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients. |
